Efficacy and gastrointestinal tolerability of methotrexate in late-onset rheumatoid arthritis patients: a prospective cohort study

Egyptian Rheumatology and Rehabilitation

Table 2 Logistic regression analysis of the impact factors on remission in LORA patients

Variable	p-value	OR	95% CI for OR
Age	0.430	0.990	0.967–1.015
Seropositivity	0.980	0.991	0.495–1.985
Large joint inv.	0.743	1.111	0.593–2.080
Only large joint	0.657	0.786	0.271–2.279
Erosive RA	0.936	1.028	0.522–2.023
Extraarticular man.	0.456	0.606	0.163–2.257
Disease duration	0.763	1.010	0.947–1.076
DAS 28	0.000^*	3.688	2.013–6.755
CRP	0.323	0.994	0.981–1.006

LORA late-onset rheumatoid arthritis, RA rheumatoid arthritis, DAS28 disease activity score-28, CRP C-reactive protein, OR odds ratio
^*Means significance (p ≤ 0.05 is statistically significant)